Cyberonics on course to financial recovery
This article was originally published in Clinica
Cyberonics' efforts to kick its finances back into shape look to be paying off as the neuromodulation technology specialist succeeded in achieving its first operating profit in over three years, as well as positive operating cash flow.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Genfit will delay unblinding of data from its nearly complete Phase III study of elafibranor to get insight from the FDA on statistical methods in order to optimize its NDA.
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.